Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 in refractory MS
2024-517601-82-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Apr 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2 trial of zamtocabtagene autoleucel in multiple sclerosis (MS), sponsored by Miltenyi Biomedicine GmbH. Planned start Apr 2026; status: authorised.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-517601-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517601-82-00.